Empirical therapy of community-acquired pneumonia: Advancing evidence or just more doubt?

JAMA - Journal of the American Medical Association

Volumn 314, Issue 4, 2015, Pages 396-397

  Mandell, Lionel A ^a   Waterer, Grant W ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CLARITHROMYCIN; MACROLIDE; OXYGEN; ANTIINFECTIVE AGENT; BETA LACTAM;

BODY TEMPERATURE; BREATHING RATE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; HAZARD RATIO; HEART RATE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; IMMUNOCOMPETENCE; INTENSIVE CARE UNIT; LEGIONELLA; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; LENGTH OF STAY; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); METHODOLOGY; MORTALITY; MULTICENTER STUDY (TOPIC); MYCOPLASMA PNEUMONIAE; OPEN STUDY; OXYGEN SATURATION; PATHOGENESIS; PATIENT SELECTION; PNEUMONIA SEVERITY INDEX; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SAMPLE SIZE; STAPHYLOCOCCUS AUREUS; SWITZERLAND; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; LEGIONNAIRES' DISEASE; PNEUMONIA, BACTERIAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; HUMANS; LEGIONNAIRES' DISEASE; MACROLIDES; PNEUMONIA, BACTERIAL;

EID: 84938399879     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.3858     Document Type: Review

References (9)

1. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):3-9.
2. Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther. 2010;32(2):293-299.
3. Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines. Arch Intern Med. 2009;169(16):1515-1524.
4. Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2012;55(3):371-380.
5. Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy vs β-lactam monotherapy for the treatment of community-acquired pneumonia in adults. J Antimicrob Chemother. 2014;69(6):1441-1446.
6. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia. Chest. 2007; 131(2):466-473.
7. Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia. JAMA Intern Med. 2014;174 (12):1894-1901.
8. Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH. How to use a noninferiority trial. JAMA. 2012;308(24):2605-2611.
9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.